Fresh analysis suggests that people who stop using blockbuster slimming jabs like Mounjaro or Wegovy tend to recover shed pounds at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Research printed in a major medical journal demonstrates that while obese individuals often shed substantial amounts of their total mass while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"People purchasing these medications must be informed of the risk of quick weight regain when the therapy ends," warns lead investigator Dr. Susan Jebb.
That rate of recovery suggests a reversion to original mass in about 18 months.
Analyzing Treatments
The analysis, which looked at 37 of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with other pills.
Researchers note that people who lose weight through dieting typically have a slower creep back—around 0.1 kg a month—after stopping.
Explaining the Rapid Rebound
Nutrition scientists propose the way of the drugs is key to understanding the accelerated weight return.
GLP-1 drugs mimic a natural hormone called GLP-1, which helps regulate hunger.
"Artificially providing GLP-1 concentrations several times higher than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and could reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement results in appetite is uncontrolled, making binge eating much more probable."
An Ongoing Condition?
Medical guidelines suggest the jabs for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
Many experts contend that, considering the significant potential of weight regain, the therapy is often ongoing.
This perspective is echoed by drug manufacturers, who say that the findings "emphasize the long-term nature of excess weight," akin to managing diseases like diabetes.
Patient Accounts
Users who have discontinued the medication explain a intense resurgence of cravings.
"It felt as if something flipping and you become starving," recalled one woman.
The struggle is exacerbated if users have not adopted sustainable dietary or behavioural modifications during therapy.
Widespread Use
Recent estimates suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with interest being substantial.
- Adoption is higher among females compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a standalone cure and long-term success relies on combined behavioural changes.
